Ipilimumab 200mg/40ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ipilimumab
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ipilimumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ipilimumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Ipilimumab on the MHRA register
Yervoy 200mg/40ml concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(15)
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Melanoma: assessment and management (NG14)
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · Randomised trials: 36 · 2014–2026
Showing the 50 most relevant studies, sorted by most relevant.
Thomas Cheung Yau, P. Galle, T. Decaens, et al.
Lancet, 2025
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Phenylurea Compounds
D. Schadendorf, F. Hodi, C. Robert, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
L. Paz-Ares, T. Ciuleanu, M. Cobo, et al.
The Lancet. Oncology, 2021
P. Baas, A. Scherpereel, A. Nowak, et al.
Lancet, 2021
T. Cascone, W. William, A. Weissferdt, et al.
Nature Medicine, 2021
N. Dizman, L. Meza, P. Bergerot, et al.
Nature Medicine, 2022
F. Hodi, V. Chiarion-Sileni, R. Gonzalez, et al.
The Lancet. Oncology, 2018
T. Yau, Yoon-Koo Kang, Tae-You Kim, et al.
JAMA Oncology, 2020
F. Hodi, J. Chesney, A. Pavlick, et al.
The Lancet. Oncology, 2016
T. Beer, E. Kwon, C. Drake, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
14.7 days
Mechanism
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that compete…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
65.8µg/mL
[L12126]
Data regarding the AUC and Tmax of ipilumumab are not readily available.
[A35118][L12126]
Half-life
14.7 days
[A35118]
Protein binding
[L12126]
Volume of distribution
7.21L
[A35118]
Metabolism
[L12126][L12642]
…
Elimination
[L12126]
Clearance
15.3 mL
[A35118]
Systemic clearance increases proportionally with body weight.
[L12642]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Ipilimumab was granted FDA approval on 25 March 2011.[L12126]
Melanoma
- Treatment of unresectable or metastatic melanoma in adult and pediatric patients ≥12 years old, alone or in combination with [nivolumab]
- Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of >1 mm who have undergone complete resection, including total lymphadenectomy
Renal Cell Carcinoma (RCC)
- First-line treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma in combination with nivolumab
Colorectal Cancer
- In combination with nivolumab, treatment of patients ≥12 years old with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer
Hepatocellular Carcinoma
- In combination with nivolumab, first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma
- In combination with nivolumab, treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib
Non-Small Cell Lung Cancer (NSCLC)
- Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1, with no EFGR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab
- Treatment of adult patients with metastatic or recurrent non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy
Malignant Pleural Mesothelioma
- Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1134 interactions
[L12126]
However, the most common adverse reactions to ipilumumab are fatigue, diarrhea, pruritus, rash, and colitis.
[L12126]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L12126]
Data regarding the AUC and Tmax of ipilumumab are not readily available.
[A35118][L12126]
[A35118]
[L12126]
[A35118]
[L12126][L12642]
Because ipilimumab is a protein, it is expected to be degraded into small peptides and amino acids by proteolytic enzymes.
[A35122]
[L12126]
[A35118]
Systemic clearance increases proportionally with body weight.
[L12642]
Proteins and enzymes this drug interacts with in the body
ATC L01FX04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ipilimumab
Additional database identifiers
Drugs Product Database (DPD)
21164
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2505
GenAtlas
CTLA4
GeneCards
CTLA4
GenBank Gene Database
AF411058
GenBank Protein Database
17646228
Guide to Pharmacology
2743
UniProt Accession
CTLA4_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72